Amivantamab for advanced lung cancer with EGFR mutations
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This Phase 2 study tests amivantamab (an antibody medicine) in people with advanced or metastatic non-small cell lung cancer that has specific EGFR gene changes. It may help shrink tumors or control cancer when standard curative treatments aren’t possible.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or metastatic non-small cell lung cancer that can’t be cured with surgery or chemoradiation
- Your tumor has an EGFR mutation in specific types (exon 19 deletion or L858R, or exon 20 insertion for a specific group)
- You must be in the right treatment “cohort” based on what you’ve had before (including whether you previously took osimertinib or amivantamab+lazertinib)
- You must have at least one measurable tumor spot (unless your only target was previously treated with radiation, and it has grown since)
- You cannot have had interstitial lung disease (ILD), drug-related lung scarring, or radiation pneumonitis
- Your overall health must be strong enough (blood counts, liver and kidney tests, and heart function), and your performance status must be 0–1
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving new drugs (amivantamab plus either lazertinib or chemotherapy) before surgery helps people with a specific type of lung cancer that can be removed. The goal is to shrink tumors and improve surgery outcomes.
This trial tests two treatment combinations for people with a specific type of advanced lung cancer that has an EGFR mutation. One group gets amivantamab plus lazertinib, and the other gets amivantamab plus chemotherapy. The goal is to see which combo works better.
This study looks at how well a treatment called amivantamab works in people with a specific type of advanced lung cancer (EGFR-mutated non-small cell lung cancer). It aims to track real-world outcomes in patients who are starting amivantamab for the first time.
This trial tests a new combination of two targeted drugs (amivantamab and olomorasib) for people with advanced lung cancer that has a specific KRAS G12C mutation. It's for those whose cancer has grown despite prior chemotherapy and immunotherapy.
This trial tests a drug called amivantamab, either alone or with other treatments, for people with head and neck cancer that has spread or come back. The goal is to see if the drug can help shrink tumors or control the cancer.
This trial tests a new drug, amivantamab, given before surgery for people with a specific EGFR-mutated lung cancer. It aims to shrink tumors and improve surgical outcomes, and may be combined with standard chemotherapy in some patients.
Hear when a new Carcinoma, Non-Small-Cell Lung trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.